Cargando…

Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer

BACKGROUND: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is a mitochondrial bifunctional enzyme encoded in the nucleus. It plays a significant role in the regulation of glucose, nucleic acid, and folate metabolism, and maintains redox balance in the cells. The present study aimed at elucidatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hao, Zhu, Shuangli, Zhou, Haiting, Li, Rui, Xia, Xiaohui, Xiong, Huihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885267/ https://www.ncbi.nlm.nih.gov/pubmed/36726381 http://dx.doi.org/10.3389/fonc.2023.1098357

Ejemplares similares

Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer
por: Wu, Song, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer
por: Zhou, Yueyuan, et al.
Publicado: (2022)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
por: Zhang, Hao, et al.
Publicado: (2022)

MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study
por: Jiang, Weihua, et al.
Publicado: (2021)

Prognostic Biomarkers on a Competitive Endogenous RNA Network Reveals Overall Survival in Triple-Negative Breast Cancer
por: Qin, Wenxing, et al.
Publicado: (2021)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

Upregulation of the ferroptosis-related STEAP3 gene is a specific predictor of poor triple-negative breast cancer patient outcomes
por: Yuan, Lifang, et al.
Publicado: (2023)

MTHFD1L-Mediated Redox Homeostasis Promotes Tumor Progression in Tongue Squamous Cell Carcinoma
por: Li, Hao, et al.
Publicado: (2019)

Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer
por: Li, Meng, et al.
Publicado: (2022)

Comprehensive analysis of prognostic value, immune implication and biological function of CPNE1 in clear cell renal cell carcinoma
por: Zhou, Haiting, et al.
Publicado: (2023)

Propofol Inhibits Proliferation and Augments the Anti-Tumor Effect of Doxorubicin and Paclitaxel Partly Through Promoting Ferroptosis in Triple-Negative Breast Cancer Cells
por: Sun, Chen, et al.
Publicado: (2022)

Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer
por: Wang, Kaili, et al.
Publicado: (2022)

Novel Prognostic Markers in Triple-Negative Breast Cancer Discovered by MALDI-Mass Spectrometry Imaging
por: Phillips, Leo, et al.
Publicado: (2019)

Prognostic Factor Analysis and Model Construction of Triple-Negative Metaplastic Breast Carcinoma After Surgery
por: Zhu, Keying, et al.
Publicado: (2022)

Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer
por: Zheng, Yi-Zi, et al.
Publicado: (2022)

Identification of Key Genes Affecting the Tumor Microenvironment and Prognosis of Triple-Negative Breast Cancer
por: Yi, Jiarong, et al.
Publicado: (2021)

Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells
por: Liu, Tingting, et al.
Publicado: (2021)

Transcriptome Analysis Reveals MFGE8-HAPLN3 Fusion as a Novel Biomarker in Triple-Negative Breast Cancer
por: Wang, Meng-Yuan, et al.
Publicado: (2021)

MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review
por: Volovat, Simona Ruxandra, et al.
Publicado: (2020)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?
por: Zhu, Zhiyuan, et al.
Publicado: (2020)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

CTSL, a prognostic marker of breast cancer, that promotes proliferation, migration, and invasion in cells in triple-negative breast cancer
por: Zhang, Lianmei, et al.
Publicado: (2023)

Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
por: Wu, Qiang, et al.
Publicado: (2019)

Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC)
por: Kulasinghe, Arutha, et al.
Publicado: (2022)

Verification and Validation of a Four-Gene Panel as a Prognostic Indicator in Triple Negative Breast Cancer
por: Pariyar, Mamta, et al.
Publicado: (2022)

Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer
por: Ruan, Yuxia, et al.
Publicado: (2023)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

PUS1 is a novel biomarker for predicting poor outcomes and triple-negative status in breast cancer
por: Fang, Zheng, et al.
Publicado: (2022)

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
por: Spira, Alexander, et al.
Publicado: (2022)

Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer
por: Fang, Kun, et al.
Publicado: (2022)

Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer
por: Sun, Jiale, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qbo20cvsm0m5tqlkg2sbl5c4i0